Navigating the economic value of treatment sequencing in large B-cell lymphoma: insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in Brazil

Administering CAR T therapies like axi-cel before epcoritamab or SoC in R/R DLBCL can lead to substantial cost offsets as fewer patients ultimately progress to subsequent treatment lines. Optimal R/R DLBCL outcomes and costs can be achieved in Brazil through maximizing the potential for cure by treating eligible patients with axi-cel ahead of other available therapies.